Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urothelial Bladder Cancer 1Recurrence 1Disease Progression 1

Interventions

Cyclophosphamide 27fludarabine 19Dexamethasone 18pembrolizumab 12Rituximab 12Etoposide 11venetoclax 10pomalidomide 9Gemcitabine 9Lenalidomide 8fludarabine phosphate 7daratumumab 7Bortezomib 7glofitamab 6carfilzomib 6Vincristine 6obinutuzumab 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Doxorubicin 5Cytarabine 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Carboplatin 4Azacitidine 4zanubrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Multiparametric Magnetic Resonance Imaging × 90 days × Clear all
NCT06126172 2026-03-20

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

Chang Gung Memorial Hospital

Phase NA Active not recruiting
125 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡